INFORMATION

MAT-NC-NON-2024-00059 04.2024 exp. 29.9.2024

NAPC

NORDIC ADVANCED PROSTATE CANCER CAMP

SEPTEMBER 27–28, 2024, STENINGEVIK STOCKHOLM, SWEDEN

BLOOM ONCOLOGY

Part of the
Astellas BLOOM programme

The NAPC Camp aims to provide:

- basic knowledge, latest update in order to advance their skills of all aspects in management of patients with advanced prostate cancer.
- familiarization with how and when to use systemic medical treatment for this patient group.
- stimulation of interdisciplinary understanding and interaction among specialist groups.

NAPC Camp faculty



Andreas Røder
MD, PhD, clinical professor of urology at University of Copenhagen, Senior Physician at Rigshospitalet - Blegdamsvej (Centre for Cancer and Organ Diseases (CKO) - Department of Urology)



Thomas Helgstrand
MD, PhD, dept. of urology, Copenhagen University Hospital, Rigshospitalet and clinical associate professor at University of Copenhagen



Katarina Puco
MD, oncologist, Lovisenberg Diaconal Hospital (Department of oncology, haematology and palliative care) and Oslo University Hospital (Institute for Cancer Research



Okko-Sakari Kääriäinen
Medical Oncologist in Kuopio University Hospital, Finland



Jon Kindblom
MD, PhD, clinical oncologist, Senior Physician at Sahlgrenska University Hospital (Department of Oncology)

We are delighted to extend an invitation to a program dedicated to exploring the latest advancements in the field of prostate cancer. Prostate cancer stands as one of the most prevalent malignancies affecting men globally, presenting unique challenges in diagnosis, treatment, and survivorship. However, recent years have witnessed remarkable progress in various aspects of prostate cancer research and clinical practice, offering new hope and opportunities for improved outcomes.

NAPC
NORDIC ADVANCED PROSTATE CANCER
CAMP

Agenda September 27–28, 2024 at Steningevik Stockholm, Sweden

Friday 27. September

11.00–12.30 **Arrival and lunch**
12.30–12.50 **Introduction to the course and day 1: Biochemical recurrence after curative therapy**, *Andreas Røder*
12.50–13.15 **State of the Art: Radiotherapy – overview of clinical trials**, *Jon Kindblom*
13.15–13.30 Case presentation, *Andreas Røder / Thomas Helgstrand*
13.30–14.00 Group case discussion
(mixed groups + with all faculty members, one / group)
Salvage radiotherapy: radiation field with or without lymph nodes?
Adjuvant hormone therapy? Type and duration
Other considerations
14.00 - 14.15 Group findings
14.15 - 14.40 **Coffee break**
14.40 - 14.55 **Introduction: 2nd biochemical relapse – what now?**
14.55–15.15 **State of the Art: Hormone therapy for hormone sensitive non-metastatic disease**, *Jon Kindblom*
15.15–15.35 **Group case discussion** (mixed groups + all faculty members, one / group), *Andreas Røder / Thomas Helgstrand*
Treatment options
Other considerations
16.05–16.20 Group findings
16.20–16.40 Closing remarks for day 1, *Andreas Røder*
18.30–20.30 **Dinner**

Saturday 28. September

8.00–8.05 **Introduction for day 2: Hormone sensitive metastatic prostate cancer**, *Andreas Røder*
8.05–8.25 **State of the art: Overview of drugs available in HSPC**, *Katarina Puco*
8.25–8.35 Case presentation, *Okko Kääriäinen / Katarina Puco*
8.35–9.20 Group case discussion (mixed groups + with faculty members, one / group)
Treatment options
Imaging and other considerations
9.20–9.35 Group findings
9.35–9.55 **Coffee break**
9.55–10.25 **State of the Art: Genomic testing**, *Andreas Røder*
10.25–11.10 **State of the art: Emerging treatments options in mCRPC**, *Okko Kääriäinen*
PARP
Theranostics
11.10–11.40 Questions from the group and discussion, *all faculty*
11.40–11.55 **Summary and thank you**, *Andreas Røder*
11.55–12.40 **Lunch**

HOW TO ATTEND

Denmark
Astellas respekterer samarbejdsaftalerne mellem ENLI og de enkelte regioner. Invitationen til eventen vil blive sendt til den respektive sygehusledelse/afdelingsledelse, som træffer beslutning om deltagelse, herunder hvilke medarbejdere der deltager i aktiviteten.

Finland
Kutsut lähetetään asianomaisen klinikan johtajalle alalla sovellettavien sääntöjen mukaisesti.

Norway
Invitasjon vil bli sendt i henhold til gjeldende regelverk ved de respektive helseforetak.

Sweden
Information om överenskommelse kring samverkansformer mellan läkemedelsföretag och medarbetare i den offentliga hälso- och sjukvården finns på www.lif.se. Denna inbjudan har skickats till verksamhetschefer inom urologi och onkologi med kopia till enskilda medarbetare samt till berörda läkemedelskommittéer. Mötet arrangeras och finansieras fullt ut av Astellas Pharma.

astellas

Astellas Pharma a/s | Arne Jacobsens Allé 15 | 2300 København S | Telefon 4343 0355 | kontakt.dk@astellas.com | www.astellas.dk

Astellas does not pay for or facilitate any spouses, partners or other persons to accompany invited attendees to meetings or associated activities, unless they qualify as an attendee in their own right.